Source: https://www.osu.cz/roman-hajek/57416/
Timestamp: 2019-04-19 15:27:27+00:00

Document:
titul, jméno, příjmení: prof. MUDr. Roman Hájek, CSc.
Adamusová, L., Kořístek, Z., Smejkalová, J., Navrátil, M., Grebeníček, L., Tvrdá, I., Michalíková, M. a Hájek, R. Automatizované promývání transplantátů krvetvorných buněk pro autologní použití. Transfuze a hematologie dnes. 2018, 24(2), s. 115-122. ISSN 1213-5763.
Jelínek, T., Fečková Mihályová, J. a Hájek, R. CD38 cílená léčba u mnohočetného myelomu. Vnitřní lékařství. 2018, 64(10), s. 939-948. ISSN 0042-773X.
Hájek, R., Usmani, S., Hoering, A., Cavo, M., San Miguel, J., Goldschimdt, H., Turesson, I., Lahuerta, J., Attal, M., Barlogie, B., Lee, J., Kumar, S., Lenhoff, S., Morgan, G., Rajkumar, S., Durie, B. a Moreau, P. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Blood Cancer Journal. 2018, č. 8, s. 1-7. ISSN 2044-5385.
Hoering, A., Cavo, M., Usmani, S., San Miguel, J., Goldschimdt, H., Turesson, I., Lahuerta, J., Attal, M., Barlogie, B., Lee, J., Kumar, S., Lenhoff, S., Morgan, G., Rajkumar, S., Durie, B., Moreau, P. a Hájek, R. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Blood Cancer Journal. 2018, 8(123), s. 1-7. ISSN 2044-5385.
Hájek, R., Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastritis, E., van de Donk, N., Gay, F., Hegenbart, U., Zweegman, S., Bruno, B., Straka, C., Dimopoulos, M., Einsele, H., Boccadoro, M., Sonneveld, P., Engelhardt, M. a Terpos, E. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018, 9(32), s. 1883-1898. ISSN 0887-6924.
Gay, F., Engelhardt, M., Terpos, E., Wasch, R., Giaccone, L., Auner, H., Caers, J., Gramatzki, M., van de Donk, N., Oliva, S., Zamagni, E., Garderet, L., Straka, C., Hájek, R., Ludwig, H., Einsele, H., Dimopoulos, M., Boccadoro, M., Kroger, N. a Cavo, M. et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. HAEMATOLOGICA. 2018, roč. 103, s. 197-211. ISSN 0390-6078.
Gay, F., Jackson, G., Rosinol, L., Holstein, S., Moreau, P., Spada, S., Davies, F., Lahuerta, J., Leleu, X., Bringhen, S., Evangelista, A., Hulin, C., Panzani, U., Cairns, D., Di Raimondo, F., Macro, M., Liberati, A., Pawlyn, C., Offidani, M. a Spencer, A. et al. Maintenance Treatment and Survival in Patients With Myeloma A Systematic Review and Network Meta-analysis. Jama Oncology. 2018, roč. 4, 4(10), s. 1389-1397. ISSN 2374-2437.
Hájek, R., Jurczyszyn, A., Davila, J., Kortüm, K., Jayabalan, D., Vij, R., Fiala, M., Milunovic, V., Chim, C., Wiśniewska-Piaty, K., Waszczuk-Gajda, A., Crusoe, E., Robak, P., Raźny, M., Zawirska, D., Bittrich, M., Nahi, H., Liu, H., Castillo, J. a Vesole, D. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. Leukemia and Lymphoma. 2018, č. červenec, s. 1-6. ISSN 1042-8194.
Kufová, Z., Ševčíková, T., Januska, J., Vojta, P., Boday, A., Vanickova, P., Filipová, J., Growková, K., Jelínek, T., Hajduch, M. a Hájek, R. Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing. JOURNAL OF CLINICAL PATHOLOGY. 2018, roč. 71, s. 687-694. ISSN 0021-9746.
Brozova, L., Jarkovsky, J., Pour, L., Minarik, J., Jungova, A., Gregora, E., Spicka, I., Maisnar, V. a Hájek, R. Asymptomatic and treatment-requiring multiple myeloma - Data from the czech registry of monoclonal gammopathies. Klinicka Onkologie. 2017, č. 30, s. 51-59. ISSN 0862-495X.
Gay, F., Oliva, S., Petrucci, M., Montefusco, V., Conticello, C., Musto, P., Catalano, L., Evangelista, A., Spada, S., Campbell, P., Ria, R., Salvini, M., Offidani, M., Carella, A., Omede, P., Liberati, A., Troia, R., Cafro, A., Malfitano, A. a Falcone, A. et al. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. LEUKEMIA. 2017, č. 31, s. 1727-1734. ISSN 0887-6924.
Ševčíková, T., Growková, K., Kufová, Z., Filipová, J., Vrublová, P., Jelínek, T., Kořístek, Z., Kryukov, F., Kryukova, E. a Hájek, R. Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies. JOURNAL OF CLINICAL PATHOLOGY. 2017, č. 70, s. 847-853. ISSN 0021-9746.
Ludwig, H., Dimopoulos, M. A., Moreau, P., Chng, W., Goldschmidt, H., Hájek, R., Facon, T., Pour, L., Niesvizky, R., Oriol, A., Rosinol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Palumbo, A., Gillenwater, H. H., Mohamed, N. a Aggarwal, S. et al. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. LEUKEMIA & LYMPHOMA. 2017, č. 58, s. 2501-2504. ISSN 1042-8194.
Meletios, A., Stewart, A. K., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosinol, L., Siegel, D., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A., San-Miguel, J., Ludwig, H., Palumbo, A., Obreja, M., Aggarwal, S. a Moreau, P. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. BRITISH JOURNAL OF HAEMATOLOGY. 2017, č. 177, s. 404-413. ISSN 0007-1048.
Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W., Oriol, A., Orlowski, R. Z., Ludwig, H., Facon, T., Hájek, R., Weisel, K., Hungria, V., Minuk, L., Feng, S., Zahlten-Kumeli, A., Kimball, A. S. a Moreau, P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. LANCET ONCOLOGY. 2017, č. 18, s. 1327-1337. ISSN 1470-2045.
Chng, W., Goldschmidt, H., Dimopoulos, M. A., Moreau, P., Joshua, D., Palumbo, A., Facon, T., Ludwig, H., Pour, L., Niesvizky, R., Oriol, A., Rosinol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Gillenwater, H. H., Mohamed, N. a Feng, S. et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. LEUKEMIA. 2017, č. 31, s. 1368-1374. ISSN 0887-6924.
Dimopoulos , M. A., Stewart, A. K., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosinol, L., Siegel, D., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A., San-Miguel, J., Ludwig, H., Ro, S., Aggarwal, S., Moreau, P. a Palumbo, A. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. BLOOD CANCER JOURNAL. 2017, č. 7, ISSN 2044-5385.
Brozova, L., Schwarz, D., Snabl, I., Kalina, J., Pavlickova, B., Komenda, M., Jarkovsky, J., Nemec, P., Horinek, D., Stefanikova, Z., Pour, L., Hájek, R. a Maisnar, V. Czech registry of monoclonal gammopathies - Technical solution, data collection and visualisation. Klinicka Onkologie. 2017, č. 30, s. 43-50. ISSN 0862-495X.
Jelínek, T., Kořístka, M., Čermáková, Z. a Hájek, R. Daratumumab - Naděje pro myelomové pacienty, výzva pro klinické laboratoře. Klinicka Onkologie. 2017, č. 30, s. 13-19. ISSN 0862-495X.
Growková, K., Kufová, Z., Ševčíková, T., Filipová, J., Kascak, M., Jelínek, T., Grosicki, S., Barchnicka, A., Roziakova, L., Mistrik, M., Simicek, M. a Hájek, R. Diagnostic Tools of Waldenström's Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring. Klinická onkologie. 2017, č. 30, s. 81-91. ISSN 1802-5307.
Sezer, O., Beksac, M., Hájek, R., Sucak, G., Cagirgan, S., Linkesch, W., Akay, O. M., Gülbas, Z., Nahi, H., Plesner, T., Snowden, J. A., Timuragaoglu, A., Dechow, T., Lang, A., Tuglular, T., Drach, J., Armbrecht, G., Potamianou, A., Couturier, C. a Olie, R. A. et al. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. BRITISH JOURNAL OF HAEMATOLOGY. 2017, č. 178, s. 61-71. ISSN 0007-1048.
Hari, P., Mateos, M., Abonour, R., Knop, S., Bensinger, W., Ludwig, H., Song, K., Hájek, R., Moreau, P., Siegel, D., Feng, S., Obreja, M., Aggarwal, S., Iskander, K. a Goldschmidt, H. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. LEUKEMIA. 2017, č. 31, s. 2630-2641. ISSN 0887-6924.
Maluskova, D., Svobodova, I., Kucerova, M., Brozova, L., Muzik, J., Jarkovsky, J., Hájek, R., Maisnar, V. a Dusek, L. Epidemiology of multiple myeloma in the Czech Republic. Klinicka Onkologie. 2017, č. 30, s. 35-42. ISSN 0862-495X.
Steiner, N., Borjan, B., Hájek, R., Jöhrer, K., Göbel, G., Willenbacher, W., Kern, J., Gunsilius, E. a Untergasser, G. Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. Oncotarget. 2017, 8(34), s. 56243-56254. ISSN 1949-2553.
Steiner, N., Hájek, R., Sevcikova, S., Borjan, B., Jöhrer, K., Göbel, G., Untergasser, G. a Gunsilius, E. High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. PLOS ONE. 2017, č. 12, ISSN 1932-6203.
Grzasko, N., Hájek, R., Hus, M., Chocholska, S., Morawska, M., Giannopoulos, K., Czarnocki, K., Druzd-Sitek, A., Pienkowska-Grela, B., Rygier, J., Usnarska-Zubkiewicz, L., Dytfeld, D., Kubicki, T., Jurczyszyn, A., Korpysz, M. a Dmoszynska, A. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leukemia and Lymphoma. 2017, č. 58, s. 2089-2100. ISSN 1042-8194.
Castillo, J. J., Jurczyszyn, A., Brozova, L., Crusoe, E., Czepiel, J., Davila, J., Dispenzieri, A., Eveillard, M., Fiala, M. A., Ghobrial, I. M., Gozzetti, A., Gustine, J. N., Hájek, R., Hungria, V., Jarkovsky, J., Jayabalan, D., Laubach, J. P., Lewicka, B., Maisnar, V. a Manasanch, E. E. et al. IgM myeloma: A multicenter retrospective study of 134 patients. AMERICAN JOURNAL OF HEMATOLOGY. 2017, č. 92, s. 746-751. ISSN 0361-8609.
Moreau, P., Joshua, D., Chng, W., Palumbo, A., Goldschmidt, H., Hájek, R., Facon, T., Ludwig, H., Pour, L., Niesvizky, R., Oriol, A., Rosinol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Gillenwater, H. H., Mohamed, N. a Aggarwal , S. et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. LEUKEMIA. 2017, č. 31, s. 115-122. ISSN 0887-6924.
Zuchnická, J., Mihályová, J. F., Ďuraš, J. a Hájek, R. Obinutuzumab v léčbě nemocných s chronickou lymfocytární leukémií a s folikulárním lymfomem. Onkologická revue. 2017, č. 3/2017, s. 6-10. ISSN 2464-7195.
Kušnierová, P., Zeman, D., Šigutová, R., Švagera, Z., Zahradová, L. a Hájek, R. Obtižne interpretovatelné nálezy elektroforéz a imunofixací u pacientu s mnohočetným myelomem po autologní transplantaci. Klinicka Biochemie a Metabolismus. 2017, č. 25, s. 59-63. ISSN 1210-7921.
Jelínek, T., Mihalyova, J., Kascak, M., Duras, J. a Hájek, R. PD-1/PD-L1 inhibitors in haematological malignancies. IMMUNOLOGY. 2017, č. 152, s. 357-371. ISSN 0019-2805.
Jelínek, T., Hájek, R., Mihalyova, J., Kascak, M. a Duras, J. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology. 2017, 3(152), s. 357-371. ISSN 0019-2805.
Jelínek, T. a Hájek, R. PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. ONCOIMMUNOLOGY. 2017, č. 5, ISSN 2162-402X.
Ďuraš, J., Kaščák, M., Navrátil, M. a Hájek, R. Pixantron v léčbě non-hodgkinských lymfomů. Onkologická revue. 2017, č. 2, s. 4-9. ISSN 2464-7195.
Jelínek, T., Kryukova, E., Kufová, Z., Kryukov, F. a Hájek, R. Proteasome inhibitors in AL amyloidosis: focus on mechanismof action and clinical activity. Hematological Oncology. 2017, č. 35, s. 408-419. ISSN 0278-0232.
Hájek, R. a Jelínek, T. Současný algoritmus léčby nemocných s mnohočetným myelomem - kam kráčí?. Acta medicinae. 2017, 6(7-8), s. 88-92. ISSN 1805-398X.
Mikulasova, A., Wardell, C. P., Murison, A., Boyle, E. M., Jackson, G. H., Smetana, J., Kufová, Z., Pour, L., Sandecka, V., Almasi, M., Vsianska, P., Gregora, E., Kuglik, P., Hájek, R., Davies, F. E., Morgan, G. J. a Walker, B. A. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. HAEMATOLOGICA. 2017, č. 102, s. 1617-1625. ISSN 0390-6078.
Growková, K., Kryukova, E., Kufová, Z., Filipová, J., Ševčíková, T., Rihova, L., Kascak, M., Kryukov, F. a Hájek, R. Waldenström's macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection. EUROPEAN JOURNAL OF HAEMATOLOGY. 2017, č. 99, s. 469-478. ISSN 0902-4441.
Kasčák, M., Duraš, J., Navrátil, M. a Hájek, R. AUTOLOGNÍ TRANSPLANTACE KMENOVÝCH BUNĚK U WALDENSTRÖMOVY MAKROGLOBULINEMIE. Transfuze a hematologie dnes. 2016, roč. 22, s. 28-38. ISSN 1213-5763.
Dimopoulos, M., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiňol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V. a Schwarer, A. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. LANCET ONCOLOGY. 2016, roč. 17, s. 27-38. ISSN 1470-2045.
Avet-Loiseau, H., Fonseca, R., Siegel, D., A. Dimopoulus, M., Špička, I., Masszi, T., Hájek, R., Rosiňol, L., Goranova-Marinova, V., Mihaylov, G., Maisnar, V., Mateos, M. -. V., Wang, M., Niesvizky, R., Oriol, A., Jakubowiak, A., Minarik, J., Palumbo, A., Bensinger, W. a Kukreti, V. et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016, roč. 128, s. 1174-1180. ISSN 0006-4971.
Thangavadievel, S., Zelle-Riser, C., Olivier, A., Postert, B., Untergasser, G., Kern, J., Brunner, A., Gunsilius, E., Biedermann, R., Hájek, R., Pour, L., Willenbacher, W., Greil, R. a Johrer, K. CCR10/CCL27 crosstalk contributes to failure of proteasomeinhibitors in multiple myeloma. ONCOTARGET. 2016, roč. 7, s. 78605-78618. ISSN 1949-2553.
Kryukova, E., Kryukov, F. a Hájek, R. Centrosome amplification and clonal evolution in multiple myeloma: Short review. CRIT REV ONCOL HEMAT. 2016, roč. 98, s. 116-121. ISSN 1040-8428.
Kryukov, F., Nemec, P., Radova, L., Kryukova, E., Okubote, S., Minarik, J., Stefanikova, Z., Pour, L. a Hájek, R. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. J TRANSL MED. 2016, roč. 14, s. 1-9. ISSN 1479-5876.
Smetana, J., Kuglik, P., Greslikova, H., Kupska, R., Nemec, P., Mikulasova, A., Valaskova, I., Oppelt, J., Almasi, M., Krejci, M., Adam, Z., Pour, L. a Hájek, R. Clonal cytogenetics changes in progression of multiple myeloma to extramedullary relapse and plasmocellular leukemia: a case report. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY. 2016, roč. 9, s. 49-60. ISSN 1936-2625.
Besse, L., Sedlarikova, L., Greslíková, H., Kupska, R., Almasi, M., Penka, M., Jelínek, T., Pour, L., Adam, Z., Kuglik, P., Krejci, M., Hájek, R. a Ševčíková, S. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. EUR J HAEMATOL. 2016, roč. 97, s. 93-100. ISSN 0902-4441.
Kryukov, F., Kryukova, E., Brožová, L., Kufová, Z., Filipová, J., Growková, K., Ševčíková, T., Jarkovský, J. a Hájek, R. Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. GENE. 2016, roč. 591, s. 490-498. ISSN 0378-1119.
Orlowski, R. Z., Narger, A., Sonneveld, P., Bladé, J., Hájek, R., Spencer, A., Robak, T., Dmoszynska, A., Horvath, N., Spicka, I., Sutherland, H. J., Suvorov, A. N., Xiu, L., Cakana, A., Parekh, T. a San-Miguel, J. F. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. CANCER. 2016, roč. 122, s. 2050-2056. ISSN 0008-543X.
Mikulášová, A., Smetana, J., Wayhelova, M., Janyskova, H., Sandecka, V., Kufová, Z., Almasi, M., Jarkovsky, J., Gregora, E., Kessler, P., Wrobel, M., Walker, B., Wardell, C. P., Morgan, G., Hájek, R. a Kuglik, P. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. EUR J HAEMATOL. 2016, roč. 97, s. 568-575. ISSN 0902-4441.
Zuchnická, J., Fečková Mihalyová, J. a Hájek, R. Chronická lymfocytární leukemie -současné možnosti léčby. Remedia. 2016, roč. 26, s. 1-8. ISSN 0862-8947.
Fečková Mihályová, J., Ďuraš, J., Zuchnická, J., Kaščák, M. a Hájek, R. Ibrutinib v hematoonkologii. Klinická Farmakologie a Farmacie. 2016, roč. 30, s. 8-14. ISSN 1212-7973.
Jelínek, T., Kufová, Z. a Hájek, R. Immunomodulatory drugs in AL amyloidosis. CRIT REV ONCOL HEMAT. 2016, roč. 99, s. 249-260. ISSN 1040-8428.
Zuchnická, J., Fečková Mihalyová, J. a Hájek, R. Léčba starší nemocné s chronickou lymfocytární leukemií kombinací obinutuzumab a chlorambucil.. Acta medicinae. 2016, s. 44-46. ISSN 1805-398X.
Jelínek, T. a Hájek, R. Monoclonal antibodies - A new era in the treatment of multiple myeloma.. Blood reviews. 2016, roč. 30, s. 101-110. ISSN 0268-960X.
Zahradová, L., Plonková, H., Grácová, K. a Hájek, R. Nové inovativní léky v léčbě mnohočetného myelomu.. Remedia. 2016, roč. 26, s. 334-335. ISSN 0862-8947.
Magarotto, V., Bringhen, S., Offidani, M., Benevolo, G., Patriarca, F., Mina, R., Falcone, A. P., Paoli, L. D., Piatrantuono, G., Gentili, S., Musolino, C., Giuliani, N., Bernardini, A., Conticello, C., Pulini, S., Ciccone, G., Maisnar, V., Ruggeri, M., Zambello, R. a Guglielmelli, T. et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. BLOOD. 2016, roč. 127, s. 1102-1108. ISSN 0006-4971.
Kaščák, M., Kufová, Z., Growková, K. a Hájek, R. Waldenströmova makroglobulinémie v roce 2016: optimalizace imunochemoterapie s cílem minimalizace nežádoucích účinků. Onkologia pre prax. 2016, roč. 2016, č. 5, s. 291-295. ISSN 1336-8176.
Mikulášová, A., Smetana, J., Wayhelová, M., Janyskova, H., Okubote, S. A., Hájek, R. a Kuglik, P. Whole genome amplification effect on segmental copy-number changes and copy-number neutral loss of heterozygosity analysis by oligonucleotide-based array-comparative genomic hybridization in human myeloma cell line. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY. 2016, roč. 9, s. 65-69. ISSN 1936-2625.
Všianská, P., Říhová, L., Varmužová, T., Suská, R., Kryukov, F., Mikulášová, A., Kupská, R., Penka, M., Pour, L., Adam, Z. a Hájek, R. Analysis of B-cell subpopulations in monoclonal gammopathies. Clinical Lymphoma, Myeloma and Leukemia. 2015, roč. 15, s. 61-71. ISSN 2152-2650.
Ludwig, H., Greil, R., Masszi, T., Spicka, I., Shpilberg, O., Hájek, R., Dmoszynská, A., Paiva, B., Belén Vidriales, M., Esteves, G., Stoppa, A. M., Robinson, Jr., D., Chaturvedi, S., Ataman, O., Enny, C., Feng, H., Velde, H. v. d. a Viterbo, L. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. BRIT J HAEMATOL. 2015, roč. 171, s. 344-354. ISSN 0007-1048.
Stewart,M.B., A., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, Ph.D., I., Oriol, A., Hájek, R., Rosiňol, Ph.D, L., Siegel, D. S., Mihaylov, G. G., Giranova-Marinová, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V. a Minařík, J. et al. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. NEW ENGL J MED. 2015, roč. 372, s. 142-152. ISSN 0028-4793.
Besse, L., Sedlaříková, L., Kryukov, F., Nekvidová, J., Radová, L., Slabý, O., Kuglik, P., Almasi, M., Penka, M., Krejčí, M., Adam, Z., Pour, L., Ševčíková, S. a Hájek, R. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. PLOS ONE. 2015, roč. 10, s. 1-12. ISSN 1932-6203.
Terpos, E., Kleber, M., Engelhardt, M., Zweegman, S., Gay, F., Kastritis, E., van de Donk, N. W., Bruno, B., Sezer, O., Broijl, A., Bringhen, S., Beksac, M., Larocca, A., Hájek, R., Musto, P., Johnsen, H. E., Morabito, F., Ludwig, H., Cavo, M. a Einsele, H. et al. European Myeloma Network. European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. HAEMATOL-HEMATOL J. 2015, roč. 100, s. 1254-1266. ISSN 0390-6078.
Ševčíková, S., Paszeková, H., Besse, L., Sedlariková, L., Kubaczková, V., Almasi, M., Pour, L. a Hájek, R. Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. BIOMEDICAL PAPERS-OLOMOUC. 2015, roč. 159, s. 288-293. ISSN 1213-8118.
Filipová, J., Řihová, L., Vsianská, P., Kufová, Z., Kryukova, E., Kryukov, F. a Hájek, R. Flow cytometry in immunoglobulin light chain amyloidosis: Short review. LEUKEMIA RES. 2015, roč. 39, s. 1131-1136. ISSN 0145-2126.
Palumbo, A., Bringhen, S., Mateos, M., Larocca, A., Facon, T., Kumar, S. K., Offidani, M., McCarthy, P., Evangelista, A., Lonial, S., Zweegman, S., Musto, P., Terpos, E., Belch, A., Hájek, R., Ludwig, H., Stewart, A. K., Moreau, P., Anderson, K. a Einsele, H. et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. BLOOD. 2015, roč. 125, s. 2068-2074. ISSN 0006-4971.
Kufová, Z., Pika, T., Jelínek, T., Kryukov, F. a Hájek, R. Hereditární amyloidózy - etiologie, klinický obraz a léčba. Transfuze a Hematologie Dnes. 2015, roč. 21, s. 184-192. ISSN 1213-5763.
Gay, F., Oliva, S., Petrucci, M. T., Conticello, C., Catalano, L., Corradini, P., Siniscalchi, A., Magarotto, V., Pour, L., Carella, A., Malfitano, A., Petro, D., Evangelista, A., Spada, S., Pescosta, N., Omede, P., Campbell, P., Liberati, A. M., Offidani, M. a Ria, R. et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. LANCET ONCOL. 2015, roč. 16, s. 1617-1629. ISSN 1470-2045.
Sedlaříková, L., Bešše, L., Novosadová, S., Kubaczková, V., Radová, L., Staník, M., Krejčí, M., Hájek, R. a Ševčíková, S. MicroRNAs in urine are not biomarkers of multiple myeloma. Journal of Negative Results in BioMedicine. 2015, roč. 14, č. 35, s. 1-6. ISSN 1477-5751.
Drandi, D., Kubiczkova-Besse, L., Ferrero, S., Dani, N., Passera, R., Mantoan, B., Gambella, M., Monitillo, L., Saraci, E., Ghione, P., Genuardi, E., Barbero, D., Omede, P., Barberio, D., Hájek, R., Vitolo, U., Palumbo, A., Cortelazzo, S., Boccadoro, M. a Inghirami, G. et al. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma A Comparison with Real-Time PCR. J MOL DIAGN. 2015, roč. 17, s. 652-660. ISSN 1525-1578.
Jelínek, T., Kryukov, F., Říhová, L. a Hájek, R. Plasma cell leukemia: from biology to treatment. EUR J HAEMATOL. 2015, roč. 95, s. 16-26. ISSN 0902-4441.
Minarik, J., Pavlicek, P., Pour, L., Pika, T., Maisnar, V., Spicka, I., Jarkovský, J., Krejci, M., Bacovský, J., Radocha, J., Straub, J., Kessler, P., Wrobel, M., Walterova, L., Sykora, M., Obernauerova, J., Brozova, L., Gregora, E., Adamova, D. a Gumulec, J. et al. Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy. PLOS ONE. 2015, roč. 10, s. 1-10. ISSN 1932-6203.
Kubiczkova, L., Kryukov, F., Slaby, O., Dementyeva, E., Jarkovsky, J., Nekvindova, J., Radova, L., Greslikova, H., Kuglik, P., Vetesnikova, E., Pour, L., Adam, Z., Sevcikova, S. a Hájek, R. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014, roč. 99, s. 511-518. ISSN 0390-6078.
Kufová, Z., Ševčíková, Z. a Hájek, R. Detekce hereditárních amyloidóz. Klinická biochemie a metabolismus. 2014, č. 22, s. 64-68.
Engelhardt, M., Terpos, E., Kleber, M., Gay, F., Wäsch, R., Morgan, G., Cavo, M., van de Donk, N., Beilhack, A., Bruno, B., Johnsen, H. E., Hájek, R., Driessen, C., Ludwig, H., Beksac, M., Boccadoro, M., Straka, C., Brighen, S., Gramatzki, M. a Larocca, A. et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014, roč. 99, s. 232-242. ISSN 0390-6078.
Ludwig, H., Sonneveld, P., Davies, F., Blade, J., Boccadoro, M., Cavo, M., Morgan, G., de la Rubia, J., Delforge, M., Dimopoulos, M., Einsele, H., Facon, T., Goldschmidt, H., Moreau, P., Nahi, H., Plesner, T., San-Miguel, J., Hájek, R., Sondergeld, P. a Palumbo, A. European Perspective on Multiple Myeloma Treatment Strategies in 2014. Oncologist. 2014, roč. 19, s. 829-844. ISSN 1083-7159.
Dimopoulos, M. A., Palumbo, A., Hájek, R., Kropff, M., Petrucci, M. T., Lewis, P., Millar, S., Zhang, J., Mei, J. a Delforge, M. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leukemia & Lymphoma. 2014, roč. 55, s. 1489-1497. ISSN 1042-8194.
Palumbo, A., Rajkumar, S. V., San Miguel, J. F., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hájek, R., Einsele, H., Anderson, K. C., Dimopoulos, M. A., Richardson, P. G., Cavo, M., Spencer, A., Stewart, A. K., Shimizu, K., Lonial, S., Sonneveld, P., Durie, B. G. a Moreau, P. et al. International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. Journal of Clinical Oncology. 2014, roč. 32, s. 587-600. ISSN 0732-183X.
Ludwig, H., Miguel, J., Dimopoulos, M., Palumbo, A., Garcia Sanz, R., Powles, R., Lentzsch, S., Ming Chen, W., Hou, J., Jurczyszyn, A., Romeril, K., Hájek, R., Terpos, E., Shimizu, K., Joshua, D., Hungria, V., Rodriguez Morales, A., Ben-Yehuda, D., Sondergeld, P. a Zamagni, E. et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014, roč. 28, s. 981-992. ISSN 0887-6924.
Hrdlickova, R., Blahutova, S., Hájek, R. a Čermáková, Z. Management of Surgical Procedures in Patients with Inherited F VII Deficiency: Six Years of Experience. Journal of Blood Disorders & Transfusion. 2014, roč. 5, s. 1-3. ISSN 2155-9864.
Svachova, H., Kryukov, F., Kryukova, E., Sevcikova, S., Nemec, P., Greslikova, H., Rihova, L., Kubiczkova, L. a Hájek, R. Nestin expression throughout multistep pathogenesis of multiple myeloma. British Journal of Haematology. 2014, roč. 164, s. 701-709. ISSN 0007-1048.
Kubiczkova, L., Pour, L., Sedlarikova, L., Hájek, R. a Sevcikova, S. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. Journal of Cellular and Molecular Medicine. 2014, roč. 18, s. 947-961. ISSN 1582-4934.
van de Donk, N. W. C. J., Palumbo, A., Johnsen, H. E., Engelhardt, M., Gay, F., Gregersen, H., Hájek, R., Kleber, M., Ludwig, H., Morgan, G., Musto, P., Plesner, T., Sezer, O., Terpos, E., Waage, A., Zweegman, S., Einsele, H., Sonneveld, P. a Lokhorst, H. M. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014, roč. 99, s. 984-996. ISSN 0390-6078.
Hájek, R., Siegel, D., Orlowski, R. Z., Ludwig, H., Palumbo, A. a Dimopoulos, M. The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. Leukemia & Lymphoma. 2014, roč. 55, s. 11-18. ISSN 1042-8194.
Hájek, R. a Jelínek, T. Využití imunomodulačních léků u amyloidózy. Mnohočetný myelom. 2014, s. 15-22.
Ščudla, V., Adam, Z., Hájek, R., Krejčí, M., Pika, T., Maisnar, V., Flodr, P., KUFOVÁ, Z., Látalová, P., Potáčová, A., Ryšavá, R., Špička, I., Tichý, M. a Všianská, P. Diagnostika a léčba systémové AL amyloidózy. Transfuze a hematologie dnes. 2013, roč. 19, s. 7-53. ISSN 1213-5763.
Hájek, R., Plonková, H. a Jelínek, T. Mnohočetný myelom. Acta medicinae. 2013, roč. 2, s. 47-49. ISSN 1805-398X.
Hájek, R., Okubote, S. A. a Svachova, H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. BRIT J HAEMATOL. 2013, roč. 163, s. 551-564. ISSN 0007-1048.
Fernández de Larrea, C., Kyle, R. A., Durie, B. G. M., Ludwig, H., Usmani, S., Vesole, D. H., Hájek, R., San Miguel, J. F., Sezer, O., Sonneveld, P., Kumar, S. K., Mahindra, A., Comenzo, R., Palumbo, A., Mazumber, A., Anderson, K. C., Richardson, P. G., Badros, A. Z., Caers, J. a Cavo, M. et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. LEUKEMIA. 2013, roč. 27, s. 780-791. ISSN 0887-6924.
Richardson, P. G., Mitsiades, C. S., Laubach, J. P., Hájek, R., Spicka, I., Dimopoulos, M. A., Moreau, P., Siegel, D. S., Jagannath, S. a Anderson, K. C. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. LEUKEMIA RES. 2013, roč. 37, s. 829-837. ISSN 0145-2126.
Dimopoulos, M., Siegel, D. S., Lonial, S., Qi, J., Hájek, R., Facon, T., Rosinol, L., Williams, C., Blacklock, H., Goldschmidt, H., Hungia, V., Spencer, A., Palumbo, A., Graef, T., Eid, J. E., Houp, J., Sun, L., Vuocolo, S. a Anderson, K. C. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. LANCET ONCOL. 2013, roč. 14, s. 1129-1140. ISSN 1470-2045.
Hájek, R., Bryce, R., Ro, S., Klencke, B. a Ludwig, H. Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC CANCER. 2012, roč. 12, s. 1-7. ISSN 1471-2407.
Hájek, R. a Plonková, H. Kombinovaná léčba nemocných s mnohočetným myelomem - lenalidomid. Acta Medicinae. 2012, s. 53-55. ISSN 1805-398X.
Dimopoulos, M. A., Delforge, M., Hájek, R., Kropff, M., Petrucci, M., Lewis, P., Nixon, A., Zhang, J., Mei, J. a Palumbo, A. Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2012, roč. 97, s. 1-37. ISSN 1592-8721.
Plonková, H., Jelínek, T., Zahradová, L. a Hájek, R. Lenalidomid v dlouhodobé strategii léčby mnohočetného myelomu. Mnohočetný myelom. s. 15-19.
Hlavní řešitel prof. MUDr. Roman Hájek, CSc.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 v. 
 V.